TR201909286T4 - CDK9 inhibitörleri olarak polisiklik amid türevleri. - Google Patents
CDK9 inhibitörleri olarak polisiklik amid türevleri. Download PDFInfo
- Publication number
- TR201909286T4 TR201909286T4 TR2019/09286T TR201909286T TR201909286T4 TR 201909286 T4 TR201909286 T4 TR 201909286T4 TR 2019/09286 T TR2019/09286 T TR 2019/09286T TR 201909286 T TR201909286 T TR 201909286T TR 201909286 T4 TR201909286 T4 TR 201909286T4
- Authority
- TR
- Turkey
- Prior art keywords
- cancer
- amide derivatives
- lymphoma
- cdk9 inhibitors
- polycyclic amide
- Prior art date
Links
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 title abstract 2
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 title abstract 2
- -1 Polycyclic amide Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000011691 Burkitt lymphomas Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- 206010029260 Neuroblastoma Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 abstract 1
- 201000003444 follicular lymphoma Diseases 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 abstract 1
- 150000003230 pyrimidines Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Detergent Compositions (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Polyesters Or Polycarbonates (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
CDK9'u inhibe eden ve hiperproliferatif hastalıkların tedavisi için yararlı olabilen bir dizi yeni piridin veya pirimidin türevi burada sağlanır. Özel olarak, bileşikler, proliferatif hastalığın, örneğin, hematolojik maligniteler, örneğin, akut miyeloid lösemi, multipl miyelom, kronik lenfositik lösemi, diffüz büyük B hücreli lenfoma, Burkitt lenfoması, foliküler lenfoma ve katı tümörler, örneğin, meme kanseri, akciğer kanseri, nöroblastom ve kolon kanseri, dahil olmak üzere kanserin, tedavisinde işe yarar.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185852P | 2015-06-29 | 2015-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201909286T4 true TR201909286T4 (tr) | 2019-07-22 |
Family
ID=56292699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/09286T TR201909286T4 (tr) | 2015-06-29 | 2016-06-27 | CDK9 inhibitörleri olarak polisiklik amid türevleri. |
Country Status (36)
| Country | Link |
|---|---|
| US (4) | US9845331B2 (tr) |
| EP (2) | EP3313838B1 (tr) |
| JP (1) | JP6997627B2 (tr) |
| KR (1) | KR102663113B1 (tr) |
| CN (1) | CN107873028B (tr) |
| AR (1) | AR105179A1 (tr) |
| AU (1) | AU2016286200B2 (tr) |
| BR (1) | BR122019013677B1 (tr) |
| CA (1) | CA2989499C (tr) |
| CL (1) | CL2017003306A1 (tr) |
| CO (1) | CO2017013713A2 (tr) |
| CR (2) | CR20210297A (tr) |
| CY (2) | CY1122111T1 (tr) |
| DK (2) | DK3539961T3 (tr) |
| DO (2) | DOP2017000295A (tr) |
| EA (1) | EA035383B1 (tr) |
| ES (2) | ES2728356T3 (tr) |
| HR (2) | HRP20211970T1 (tr) |
| HU (2) | HUE057343T2 (tr) |
| IL (1) | IL256393B (tr) |
| LT (2) | LT3313838T (tr) |
| ME (1) | ME03404B (tr) |
| MX (1) | MX371034B (tr) |
| NI (1) | NI201700174A (tr) |
| PE (1) | PE20180530A1 (tr) |
| PH (1) | PH12017502334A1 (tr) |
| PL (2) | PL3313838T3 (tr) |
| PT (2) | PT3539961T (tr) |
| RS (2) | RS62781B1 (tr) |
| SI (2) | SI3539961T1 (tr) |
| SV (1) | SV2017005598A (tr) |
| TN (1) | TN2017000486A1 (tr) |
| TR (1) | TR201909286T4 (tr) |
| TW (1) | TWI723028B (tr) |
| WO (1) | WO2017001354A1 (tr) |
| ZA (1) | ZA201800563B (tr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200289506A1 (en) | 2017-09-25 | 2020-09-17 | Astrazeneca Ab | Combination of a btk inhibitor and an inhibitor or cdk9 to treat cancer |
| EP3694506B1 (en) * | 2017-10-09 | 2023-08-02 | Merck Sharp & Dohme LLC | Novel substituted phenyloxetane and phenyltetrahydrofuran compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
| CN108129288B (zh) * | 2017-12-27 | 2021-01-22 | 上海毕得医药科技股份有限公司 | 一种反式-3-羟基环丁基甲酸的合成方法 |
| TW202344250A (zh) | 2018-11-14 | 2023-11-16 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| CN114008046B (zh) * | 2019-06-27 | 2023-08-18 | 南京明德新药研发有限公司 | 作为cdk9抑制剂的氮杂吲哚连吡唑类化合物 |
| WO2021050824A1 (en) * | 2019-09-11 | 2021-03-18 | Prelude Therapeutics Incorporated | Cdk inhibitors and their use as pharmaceuticals |
| WO2021115335A1 (zh) * | 2019-12-09 | 2021-06-17 | 石药集团中奇制药技术（石家庄）有限公司 | 作为周期蛋白依赖性激酶9抑制剂的化合物及其应用 |
| EP4141004A4 (en) * | 2020-05-12 | 2023-08-23 | Suzhou Alphama Biotechnology Co., Ltd. | POLYCYCLIC AMIDE DERIVATIVE SERVING AS A CDK9 INHIBITOR, METHOD FOR PREPARING IT AND ITS USE |
| US20230219961A1 (en) * | 2020-05-12 | 2023-07-13 | Suzhou Alphama Biotechnology Co., Ltd. | Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof |
| JP2023542065A (ja) | 2020-06-24 | 2023-10-05 | アストラゼネカ ユーケー リミテッド | 抗体－薬物複合物及びｃｄｋ９阻害剤の組み合わせ |
| CA3188521A1 (en) | 2020-08-07 | 2022-02-10 | Zuozhong PENG | Cdk9 inhibitor and use thereof |
| TWI809330B (zh) * | 2020-11-20 | 2023-07-21 | 大陸商勁方醫藥科技(上海)有限公司 | Cdk9抑制劑的多晶型物及其製法和用途 |
| WO2022247785A1 (zh) * | 2021-05-24 | 2022-12-01 | 石药集团中奇制药技术（石家庄）有限公司 | 一种周期蛋白依赖性激酶9抑制剂的用途 |
| CN115381824A (zh) * | 2021-05-24 | 2022-11-25 | 石药集团中奇制药技术（石家庄）有限公司 | 周期蛋白依赖性激酶9抑制剂的用途 |
| CN117813289A (zh) * | 2021-07-14 | 2024-04-02 | 上海海雁医药科技有限公司 | 吡唑衍生物及其中间体和制备方法 |
| CN118613257A (zh) * | 2021-12-23 | 2024-09-06 | 鲁汶大学 | 用于抑制yap/taz-tead的四氢吡唑并嘧啶及相关类似物 |
| WO2024039210A1 (ko) | 2022-08-17 | 2024-02-22 | 한국화학연구원 | Cdk2 및/또는 cdk9의 억제 또는 분해용 화합물 및 이들의 의약 용도 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008133192A1 (ja) * | 2007-04-19 | 2008-11-06 | Takeda Pharmaceutical Company Limited | 縮合イミダゾール化合物およびその用途 |
| WO2008129070A1 (en) | 2007-04-24 | 2008-10-30 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| WO2008129071A1 (en) | 2007-04-24 | 2008-10-30 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| EP2137166B1 (en) | 2007-04-24 | 2012-05-30 | Ingenium Pharmaceuticals GmbH | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases |
| JP5566879B2 (ja) | 2007-04-24 | 2014-08-06 | インゲニウム ファーマシューティカルズ ジーエムビーエイチ | プロテインキナーゼの阻害剤 |
| WO2008132138A1 (en) | 2007-04-25 | 2008-11-06 | Ingenium Pharmaceuticals Gmbh | Derivatives of 4,6-disubstituted aminopyrimidines |
| ATE510827T1 (de) | 2007-10-12 | 2011-06-15 | Ingenium Pharmaceuticals Gmbh | Inhibitoren von proteinkinasen |
| BR112012008147A2 (pt) | 2009-09-04 | 2016-03-01 | Novartis Ag | compostos heteroarílicos como inibidores da quinase |
| US20110113038A1 (en) | 2009-11-12 | 2011-05-12 | International Business Machines Corporation | Search term security |
| GB201002911D0 (en) * | 2010-02-19 | 2010-04-07 | Medical Res Council | Compound |
| US8518948B2 (en) | 2010-03-10 | 2013-08-27 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| AR081810A1 (es) * | 2010-04-07 | 2012-10-24 | Bayer Cropscience Ag | Piridinilpirazoles biciclicos |
| WO2012066065A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | Phenyl-heteroaryl amine compounds and their uses |
| WO2012101064A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyrimidine biaryl compounds as protein kinase inhibitors |
| JP2014506878A (ja) * | 2011-01-28 | 2014-03-20 | ノバルティス アーゲー | Ｃｄｋ９阻害剤としての置換ビ−ヘテロアリール化合物およびそれらの使用 |
| WO2012101063A1 (en) * | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyridine biaryl compounds and their uses |
| EP2763993B1 (en) * | 2011-10-06 | 2017-04-19 | Bayer Intellectual Property GmbH | Heterocyclylpyri(mi)dinylpyrazole |
| AU2014244263A1 (en) | 2013-03-13 | 2015-08-13 | Abbvie Inc. | CDK9 kinase inhibitors |
| AU2014244183A1 (en) | 2013-03-13 | 2015-08-13 | Abbvie Inc. | Pyridine CDK9 kinase inhibitors |
| US9346813B2 (en) | 2013-03-14 | 2016-05-24 | Abbvie Inc. | Substituted pyrrolo[2,3-d]pyrimindines as CDK9 kinase inhibitors |
| TW201444836A (zh) | 2013-03-14 | 2014-12-01 | Abbvie Inc | 吡咯并［２，３－ｂ］吡啶ｃｄｋ９激酶抑制劑 |
-
2016
- 2016-06-27 AU AU2016286200A patent/AU2016286200B2/en active Active
- 2016-06-27 CA CA2989499A patent/CA2989499C/en active Active
- 2016-06-27 PL PL16733459T patent/PL3313838T3/pl unknown
- 2016-06-27 HU HUE19165726A patent/HUE057343T2/hu unknown
- 2016-06-27 ME MEP-2019-138A patent/ME03404B/me unknown
- 2016-06-27 SI SI201631427T patent/SI3539961T1/sl unknown
- 2016-06-27 RS RS20220005A patent/RS62781B1/sr unknown
- 2016-06-27 SI SI201630247T patent/SI3313838T1/sl unknown
- 2016-06-27 DK DK19165726.1T patent/DK3539961T3/da active
- 2016-06-27 HU HUE16733459A patent/HUE043440T2/hu unknown
- 2016-06-27 TR TR2019/09286T patent/TR201909286T4/tr unknown
- 2016-06-27 ES ES16733459T patent/ES2728356T3/es active Active
- 2016-06-27 PE PE2017002874A patent/PE20180530A1/es unknown
- 2016-06-27 KR KR1020187002262A patent/KR102663113B1/ko active IP Right Grant
- 2016-06-27 CR CR20210297A patent/CR20210297A/es unknown
- 2016-06-27 EP EP16733459.8A patent/EP3313838B1/en active Active
- 2016-06-27 JP JP2017567737A patent/JP6997627B2/ja active Active
- 2016-06-27 HR HRP20211970TT patent/HRP20211970T1/hr unknown
- 2016-06-27 EP EP19165726.1A patent/EP3539961B1/en active Active
- 2016-06-27 TN TNP/2017/000486A patent/TN2017000486A1/en unknown
- 2016-06-27 DK DK16733459.8T patent/DK3313838T3/da active
- 2016-06-27 EA EA201890094A patent/EA035383B1/ru not_active IP Right Cessation
- 2016-06-27 MX MX2017016244A patent/MX371034B/es active IP Right Grant
- 2016-06-27 BR BR122019013677-7A patent/BR122019013677B1/pt active IP Right Grant
- 2016-06-27 RS RS20190564A patent/RS58712B1/sr unknown
- 2016-06-27 US US15/193,826 patent/US9845331B2/en active Active
- 2016-06-27 PL PL19165726T patent/PL3539961T3/pl unknown
- 2016-06-27 CN CN201680029447.9A patent/CN107873028B/zh active Active
- 2016-06-27 LT LTEP16733459.8T patent/LT3313838T/lt unknown
- 2016-06-27 LT LTEP19165726.1T patent/LT3539961T/lt unknown
- 2016-06-27 CR CR20170596A patent/CR20170596A/es unknown
- 2016-06-27 PT PT191657261T patent/PT3539961T/pt unknown
- 2016-06-27 WO PCT/EP2016/064899 patent/WO2017001354A1/en active Application Filing
- 2016-06-27 PT PT16733459T patent/PT3313838T/pt unknown
- 2016-06-27 ES ES19165726T patent/ES2902148T3/es active Active
- 2016-06-28 TW TW105120362A patent/TWI723028B/zh active
- 2016-06-28 AR ARP160101956A patent/AR105179A1/es unknown
-
2017
- 2017-12-06 US US15/833,277 patent/US10717746B2/en active Active
- 2017-12-12 DO DO2017000295A patent/DOP2017000295A/es unknown
- 2017-12-15 PH PH12017502334A patent/PH12017502334A1/en unknown
- 2017-12-18 IL IL256393A patent/IL256393B/en unknown
- 2017-12-20 SV SV2017005598A patent/SV2017005598A/es unknown
- 2017-12-21 CL CL2017003306A patent/CL2017003306A1/es unknown
- 2017-12-22 NI NI201700174A patent/NI201700174A/es unknown
- 2017-12-28 CO CONC2017/0013713A patent/CO2017013713A2/es unknown
-
2018
- 2018-01-26 ZA ZA2018/00563A patent/ZA201800563B/en unknown
- 2018-09-25 DO DO2018000207A patent/DOP2018000207A/es unknown
-
2019
- 2019-04-19 HR HRP20190748TT patent/HRP20190748T1/hr unknown
- 2019-06-19 CY CY20191100636T patent/CY1122111T1/el unknown
-
2020
- 2020-07-17 US US16/931,786 patent/US11352369B2/en active Active
-
2021
- 2021-12-22 CY CY20211101125T patent/CY1125066T1/el unknown
-
2022
- 2022-04-27 US US17/660,935 patent/US20220340592A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201909286T4 (tr) | CDK9 inhibitörleri olarak polisiklik amid türevleri. | |
| CY1124476T1 (el) | Egfr αναστολεας, και παρασκευη και εφαρμογη αυτου | |
| CY1126066T1 (el) | Υποκατεστημενα παραγωγα θειενο[2,3-d]πυριμιδινης ως αναστολεις της μενινης-mll και μεθοδοι χρησης | |
| EA201990187A1 (ru) | Антипролиферационные средства на основе пиримидина | |
| EA201890158A1 (ru) | Антитела против ntb-a и связанные композиции и способы | |
| NI201800042A (es) | Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1 | |
| CY1119361T1 (el) | 3,4-διυδροισοκινολιν-2(1h)-υλικες ενωσεις | |
| PH12014502169A1 (en) | N-cyclylamides as nematicides | |
| MX2015001720A (es) | Hetero-azepinonas sustituidas. | |
| BR112017020336A2 (pt) | análogos de nucleosídeos 5?-substituídos | |
| GEP20186933B (en) | Substituted dihydroisoquinoline compounds | |
| CY1125047T1 (el) | Διεργασιες για την παρασκευη ενωσεων τυπου οξαθειαζινης | |
| BR112012029647A2 (pt) | novos derivados de pirimidinas | |
| CY1121884T1 (el) | Αντι-ογκικες ενωσεις | |
| WO2015130922A3 (en) | Small molecule hsp70 inhibitors | |
| MX2018001576A (es) | Piridinas y su uso en el tratamiento del cancer. | |
| BR112019003130A2 (pt) | agonista de ppargama para tratamento de cânceres de sangue | |
| MX2016001641A (es) | Ciclobutilcarboxamidas como nematicidas. | |
| MX2016000487A (es) | Piridina-2-carboxamidas como nematicidas. | |
| FR3027457B1 (fr) | Materiau d'electrode de formule limnxco1-xbo3, et son procede de preparation | |
| EA201992557A1 (ru) | Противоопухолевые соединения | |
| IN2013DE03665A (tr) | ||
| RU2012144143A (ru) | Способ определения чувствительности злокачественной опухоли к химиопрепарату | |
| UA104379U (uk) | Біс(оксифеніленімінометилен)дифеноли з перфторованими моно- та біфеніленовими центральними фрагментами як прекурсори для синтезу бензоксазинів | |
| EA201790651A3 (ru) | Способ лечения рака и инфаркта миокарда |